Clinically and pharmacologically relevant interactions of antidiabetic drugs
- 31 March 2016
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 7 (2), 69-83
- https://doi.org/10.1177/2042018816638050
Abstract
Patients with type 2 diabetes mellitus often require multifactorial pharmacological treatment due to different comorbidities. An increasing number of concomitantly taken medications elevate the risk of the patient experiencing adverse drug effects or drug interactions. Drug interactions can be divided into pharmacokinetic and pharmacodynamic interactions affecting cytochrome (CYP) enzymes, absorption properties, transporter activities and receptor affinities. Furthermore, nutrition, herbal supplements, patient’s age and gender are of clinical importance. Relevant drug interactions are predominantly related to sulfonylureas, thiazolidinediones and glinides. Although metformin has a very low interaction potential, caution is advised when drugs that impair renal function are used concomitantly. With the exception of saxagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitors also show a low interaction potential, but all drugs affecting the drug transporter P-glycoprotein should be used with caution. Incretin mimetics and sodium–glucose cotransporter-2 (SGLT-2) inhibitors comprise a very low interaction potential and are therefore recommended as an ideal combination partner from the clinical–pharmacologic point of view.Keywords
This publication has 86 references indexed in Scilit:
- Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trialsDiabetes, Obesity and Metabolism, 2013
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetesBMJ Open, 2012
- An overview on antidiabetic medicinal plants having insulin mimetic propertyAsian Pacific Journal of Tropical Biomedicine, 2012
- Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitusDiabetes Therapy, 2011
- The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United StatesJAMA, 2008
- Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazideBritish Journal of Pharmacology, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2008
- EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals Of The Rheumatic Diseases, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007